Join to view full profile
3400 Spruce St15 Penn TowerPhiladelphia, PA 19104
Phone+1 215-662-3914
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Tuveson, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and New York.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1997 - 2000
Johns Hopkins University School of MedicineClass of 1994
Certifications & Licensure
NY State Medical License 2013 - 2026
PA State Medical License 2003 - 2014
Publications & Presentations
PubMed
- 3 citationsSignal peptide-independent secretion of keratin-19 by pancreatic cancer cells.Philip Moresco, Jonathan P Kastan, Jung-In Yang, Rishvanth Prabakar, Francesca Minicozzi
Biorxiv. 2025-01-20 - 17 citationsMARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer.Olaf Klingbeil, Damianos Skopelitis, Claudia Tonelli, Toyoki Yoshimoto, Aktan Alpsoy
Cancer Discovery. 2024-12-02 - The evolving role for surgery in pancreatic cancer.David Tuveson, Peter Allen
Carcinogenesis. 2024-11-22
Authored Content
- Successful Creation of Pancreatic Cancer Organoids by Means of EUS-Guided Fine-NeedleJanuary 2018
Press Mentions
Targeting FGFR2 May Prevent or Delay Some KRAS-Mutated Pancreatic CancersApril 2nd, 2025- AACR Patient Advocate Forum: Patient-Centric Cancer Clinical Trial DesignFebruary 6th, 2025
- How Pancreatic Cancer Can Be Accelerated by a Splicing-Regulator ProteinApril 27th, 2023
Grant Support
- SOAT1 as a targetable dependency in Pancreatic AdenocarcinomaCOLD SPRING HARBOR LABORATORY2025–2030
- Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic CancerCOLD SPRING HARBOR LABORATORY2025–2028
- Fibroblast Heterogeneity in Pancreatic CancerCOLD SPRING HARBOR LABORATORY2021–2026
- Environmental triggers of early-onset colorectal cancer: interactions between microplastics and pks+ E coli in early-life gut colonizationCOLD SPRING HARBOR LABORATORY1997–2026
